NCT05101070 : Clinical Trial Detail - Cancer Knowledgebase (CKB)

Request Content

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

NCT ID	NCT05101070
Title	S-531011 as Monotherapy and in Combination With an Immune Checkpoint Inhibitor in Advanced or Metastatic Solid Tumors (aCCeleR8-001)
Acronym	aCCeleR8-001
Recruitment	Recruiting
Gender	both
Phase	Phase Ib/II
Variant Requirements	Yes
Sponsors	Shionogi Inc.
Indications	gastric adenocarcinoma esophagus squamous cell carcinoma lung non-small cell carcinoma pancreatic cancer renal cell carcinoma transitional cell carcinoma ovary epithelial cancer colorectal cancer cervical cancer melanoma gastroesophageal junction adenocarcinoma head and neck squamous cell carcinoma esophagus adenocarcinoma triple-receptor negative breast cancer Advanced Solid Tumor
Therapies	Pembrolizumab + S-531011 S-531011
Age Groups:	adult \| senior
Covered Countries	USA

Additional content available in CKB BOOST